Novartis Pharma AG partners with Target PharmaSolutions to support its global longitudinal observational study designed to generate real-world clinical data.
Parexel boosts its oncology team, Premier Research has a new COO joining from PPD, and SGS names a new biologics manager, among other new hires in February.
Alphabet's research organization Verily is on a mission to empower patients with their own data – and to collectively solve some of the industry’s biggest challenges, says SCOPE keynote speaker.
Houston Methodist Hospital joins the TriNetX global health research network to provide RWD for study feasibility and academic collaboration in industry-sponsored clinical trials.
Artificial intelligence works best in a standardized environment, say industry experts. Workflows and processes must first be aligned to successfully use the technology – is pharma ready?
Integrated research organizations aim to bridge the gap between clinical research and clinical health care with the use of RWD, yet, the data may not be ready for research, according to Elligo Data Scientist.
Inclusion criteria, standardized procedures, and high-quality clinician training are key to conducting clinical trials in individuals with autism spectrum disorder, says industry expert.
The goal of the learning health system is to improve based on the experiences of every participant, sharing research knowledge to drive a “person-centered future of health,” says LHC CEO.
Why do people do what they do? This is the question behavioral science aims to answer – and our understanding of which is directly relevant to the challenges facing the health care industry, says industry expert.
A pre-IND review by the US FDA has allowed Virpax to continue with NDAs for DSF100 and LBL100, two pain relief products with specialised drug delivery formulations.
A drug is only as effective as its delivery system, and the advent of new molecules and new innovations have to be matched by enhanced delivery and containment methods, suggests West Pharma exec.
Consolidating its businesses under one brand, Altasciences is transitioning to an early drug development CRO – and looking to add a CDMO to manufacture drugs up to Phase II volumes.
Proximity Health Solutions aims to tackle clinical trial recruitment by meeting patients where they live – using its access to local thought leaders and community venues to educate and enroll potential participants in close proximity to investigator sites.
Novartis exercises its option to license Ionis’ RNA-targeting cardiovascular drug, adding to its cardiovascular treatment portfolio, as Entresto reaches the three-year mark on its patent.
The pharmaceutical and biotech consultancy has opened a new office in Dublin, Ireland ahead of Brexit, the final outcomes of which remain unknown, says CEO.
Haselmeier to provide assembly, labeling, and packaging services for its drug-device combination products following recent permission given to Germany-site.
A number of companies spent the early part of the year creating and then filling new positions, which has seen another big pharma company follow the trend of appointing a chief digital officer.
Clinical trial sites are challenged by fragmented financial processes, according to a new study by the Society of Clinical Research sites and Greenphire released this week at SCOPE 2019.
Lonza enters private label partnership to manufacture and globally commercialize AllCell’s hematopoietic primary cells to provide greater access to researchers.
PPD’s agreement with China-based Happy Life Tech focuses on site selection, patient recruitment, and real-world evidence generation for customers globally.
A low volume, high margin business model will facilitate the development of new antibiotics and see big pharma return to the space, suggests Entasis CEO.
With the recent marriage between technology and science aimed at innovating aspects of clinical trials panels composed of experts from fields outside of pharma could prove to be impactful.
Artificial intelligence advances threaten data privacy, according to a new study, which found it is possible to re-identify individuals using their physical activity data.
Shimmer designed its new Verisense platform from the ground up after finding that current activity trackers fail to meet the “basic needs of the clinical research market,” says company executive.
US FDA issues draft guidance for its competitive generic therapies pathway, providing drugmakers with clarity on the designation and calling on the industry for more generic competition.
In full-year financials, AstraZeneca announced that its R&D arm, MedImmune, will be absorbed into the overall company as it restructures its R&D units into specific therapy areas.
The EMA needs to fix problems with the clinical trial registry to improve reporting across Europe, says TranspariMED founder, as seemingly small issues can “seriously hinder compliance.”